Intellia Therapeutics (NTLA) announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran in hereditary angioedema on Monday, April 27, and will host a webcast at 8:00 a.m. ET to discuss the data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws
- Roblox initiated, Target upgraded: Wall Street’s top analyst calls
- Intellia Therapeutics upgraded to Buy from Hold at JonesResearch
- Intellia Therapeutics price target raised to $15 from $9 at RBC Capital
- Intellia Therapeutics price target raised to $19 from $17 at BofA